14,302 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Acquired by Atomi Financial Group Inc.

Atomi Financial Group Inc. purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 14,302 shares of the company's stock, valued at approximately $392,000.

Several other large investors have also recently added to or reduced their stakes in BBIO. Polar Asset Management Partners Inc. acquired a new position in shares of BridgeBio Pharma during the third quarter worth approximately $1,286,000. First Turn Management LLC bought a new position in BridgeBio Pharma in the 3rd quarter worth approximately $10,178,000. Janus Henderson Group PLC lifted its holdings in BridgeBio Pharma by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company's stock worth $122,658,000 after buying an additional 505,481 shares in the last quarter. Intech Investment Management LLC bought a new position in BridgeBio Pharma in the 3rd quarter valued at $1,136,000. Finally, Principal Financial Group Inc. boosted its holdings in BridgeBio Pharma by 1.8% in the third quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock valued at $29,155,000 after acquiring an additional 19,978 shares during the last quarter. 99.85% of the stock is owned by institutional investors.

Insider Buying and Selling at BridgeBio Pharma

In other news, CFO Brian C. Stephenson sold 4,156 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $93,135.96. Following the completion of the transaction, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Neil Kumar sold 27,389 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the transaction, the chief executive officer now owns 4,897,443 shares in the company, valued at approximately $109,751,697.63. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.66% of the company's stock.

BridgeBio Pharma Trading Up 1.3 %

Shares of BBIO traded up $0.50 during mid-day trading on Friday, reaching $37.59. 1,730,131 shares of the stock traded hands, compared to its average volume of 2,329,835. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $41.04. The firm has a fifty day moving average price of $28.81 and a 200 day moving average price of $26.89. The company has a market cap of $7.10 billion, a price-to-earnings ratio of -15.60 and a beta of 1.05.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BBIO. Evercore ISI upped their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a report on Monday, December 23rd. Oppenheimer initiated coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They set a "market perform" rating for the company. Leerink Partners decreased their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a report on Thursday, October 17th. Bank of America upped their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Finally, Scotiabank raised their price objective on BridgeBio Pharma from $45.00 to $48.00 and gave the company a "sector outperform" rating in a research report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, BridgeBio Pharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.08.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.